Lormalzi (donanemab) from Eli Lilly and Company is the first drug aimed at the plaques that cause Alzheimer’s to be launched in India. It is meant to be used in people experiencing early Alzheimer’s dementia, such as with mild cognitive impairment and mild dementia. The treatment has been given approval by the Central Drugs Standard Control Organization (CDSCO) with the objective to slow down thinking and memory impairments due to the clearance of amyloid plaques from the brain. The drug is given via intravenous (into a vein) infusion every four weeks. The launch has been hailed as a significant step towards revolutionising neurological healthcare in India, particularly considering the increasing prevalence of dementia among the elderly population.
Alzheimer’s Therapy in India: Key Facts About Donanemab (Lormalzi)
The brand name of the medicine used to treat Alzheimer’s disease that was introduced in India is Lormalzi.
Eli Lilly and Company has begun rolling out the therapy.
It is India’s first antibody which targets amyloid plaques, a first-in-class Alzheimer’s drug.
It is approved for use in people who have mild dementia (from Alzheimer’s disease) and mild cognitive impairment.
The mechanism of action of Donanemab is through removing amyloid beta plaques from the brain.
Amyloid plaques are deposits that appear with Alzheimer’s and are a symptom of its progression.
Medicine is given into a vein every 4 weeks.
In India the therapy got approval from the CDSCO (Central Drugs Standardization Control Organization).
The cost of one 350 mg vial is around ₹91,688.
The therapy reportedly helped to slow mental slowing in patients with early symptoms.
Alzheimer’s is the most prevalent type of dementia in the world.
The increasing life expectancy among Indians is causing an alarming rise in the number of patients suffering from dementia.
But these experts believe that early diagnosis is essential to good treatment results.
Donanemab’s launch marks a pivotal achievement in Neurological Healthcare in India.
Alzheimer’s Disease PYQs for Competitive Exams
Conclusion: Alzheimer’s Therapy Launch
Donanemab (Lormalzi) is a major breakthrough in Alzheimer’s treatment in India. A therapy that targets the root cause of Alzheimer’s Disease can be used by the initial patients suffering from early-stage Alzheimer’s, for the first time in India. While the treatment is still costly, experts say it will help make treatment more cost effective and promote early diagnosis in the country. This therapy could be a key part of India’s healthcare system in coming years, given the projected steep increase in the number of cases linked to dementia diseases. Future solutions will certainly count on further study, awareness and budget friendly availability.
